Delving into the Latest Updates on PF-07291177 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization-

Inactive Organization

Pfizer Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of the study is to learn about the safety, tolerability (the extent to which side effects can be tolerated), and plasma pharmacokinetics (PK) (PK helps us understand how the drug is changed and eliminated from body after you take it) of PF-07291177 after administration of escalating, single, doses by mouth.

Start Date15 Aug 2022

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with PF-07291177

Login to view more data

100 Translational Medicine associated with PF-07291177

Login to view more data

100 Patents (Medical) associated with PF-07291177

Login to view more data

100 Deals associated with PF-07291177

Login to view more data